Cybin, Kernel tout study of ketamine's effects on brain

By The Science Advisory Board staff writers

May 9, 2022 -- Kernel's neuroimaging technology successfully measured the neuroeffect of ketamine over 11 days, according to the results of a pilot study from the biopharmaceutical firm Cybin.

Researchers used Kernel's Flow headset to measure cortical hemodynamics in research subjects given ketamine, which gave individuals an altered state of consciousness. The technology measured the neuroeffect of the drug and confirmed changes in functional connectivity that are consistent with current scientific research, according to the results.

Absolute functional connectivity in a research subject for minutes five to 15 after he received the intramuscular injection of ketamine
(Top) Absolute functional connectivity in a research subject for minutes five to 15 after he received the 57.75-mg intramuscular injection of ketamine. (Bottom) Subject's relative functional connectivity changes after the Ketamine took effect starting at minutes 15 to 25. Images courtesy of Kernel.

For the pilot study, participants received either a low dose of ketamine and/or a placebo while wearing the Flow headset, which is equipped with sensors to record brain activity. Participants' experiences are being reported using structured questionnaires and validated assessments during study visits and at follow-up.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.